{"name":"H. Lundbeck A/S","slug":"h-lundbeck-a-s","ticker":"","exchange":"","domain":"lundbeck.com","description":"","hq":"Valby","founded":0,"employees":"","ceo":"Q136192540","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Lu AA24530","genericName":"Lu AA24530","slug":"lu-aa24530","indication":"Treatment of schizophrenia","status":"phase_2"},{"name":"Zerdol","genericName":"SERTINDOLE","slug":"sertindole","indication":"Schizophrenia","status":"marketed"},{"name":"Adjunct brexpiprazole","genericName":"Adjunct brexpiprazole","slug":"adjunct-brexpiprazole","indication":"Adjunctive treatment of major depressive disorder in adults","status":"phase_3"},{"name":"Aripiprazole and aripiprazole once-monthly","genericName":"Aripiprazole and aripiprazole once-monthly","slug":"aripiprazole-and-aripiprazole-once-monthly","indication":"Schizophrenia","status":"phase_3"},{"name":"Lu AA21004","genericName":"Lu AA21004","slug":"lu-aa21004","indication":"Major depressive disorder","status":"phase_3"},{"name":"MK0928, gaboxadol","genericName":"MK0928, gaboxadol","slug":"mk0928-gaboxadol","indication":"Insomnia","status":"phase_3"},{"name":"Memantine (once daily)","genericName":"Memantine (once daily)","slug":"memantine-once-daily","indication":"Moderate to severe Alzheimer's disease","status":"marketed"},{"name":"Memantine (twice daily)","genericName":"Memantine (twice daily)","slug":"memantine-twice-daily","indication":"Moderate to severe Alzheimer's disease","status":"marketed"},{"name":"Paliperidone and paliperidone palmitate","genericName":"Paliperidone and paliperidone palmitate","slug":"paliperidone-and-paliperidone-palmitate","indication":"Schizophrenia","status":"phase_3"},{"name":"Vortioxetine (Lu AA21004)","genericName":"Vortioxetine (Lu AA21004)","slug":"vortioxetine-lu-aa21004","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"ALD1910","genericName":"ALD1910","slug":"ald1910","indication":"Other","status":"phase_1"},{"name":"Azilect®","genericName":"Azilect®","slug":"azilect","indication":"Other","status":"marketed"},{"name":"Droxidopa capsules","genericName":"Droxidopa capsules","slug":"droxidopa-capsules","indication":"Other","status":"marketed"},{"name":"Lu AG09222","genericName":"Lu AG09222","slug":"lu-ag09222","indication":"Other","status":"phase_2"},{"name":"ldalopirdine 120 mg","genericName":"ldalopirdine 120 mg","slug":"ldalopirdine-120-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ALD1910","genericName":"ALD1910","slug":"ald1910","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Lu AA24530","genericName":"Lu AA24530","slug":"lu-aa24530","phase":"phase_2","mechanism":"Selective 5-HT6 receptor antagonist","indications":["Treatment of schizophrenia"],"catalyst":""},{"name":"Zerdol","genericName":"SERTINDOLE","slug":"sertindole","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 2C","indications":["Schizophrenia"],"catalyst":""},{"name":"Adjunct brexpiprazole","genericName":"Adjunct brexpiprazole","slug":"adjunct-brexpiprazole","phase":"phase_3","mechanism":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, used as an adjunctive treatment to enhance antidepressant efficacy.","indications":["Adjunctive treatment of major depressive disorder in adults"],"catalyst":""},{"name":"Aripiprazole and aripiprazole once-monthly","genericName":"Aripiprazole and aripiprazole once-monthly","slug":"aripiprazole-and-aripiprazole-once-monthly","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors, which stabilizes dopamine and serotonin neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Irritability associated with autism spectrum disorder"],"catalyst":""},{"name":"Azilect®","genericName":"Azilect®","slug":"azilect","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Droxidopa capsules","genericName":"Droxidopa capsules","slug":"droxidopa-capsules","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lu AA21004","genericName":"Lu AA21004","slug":"lu-aa21004","phase":"phase_3","mechanism":"Lu AA21004 is a multimodal antidepressant that acts as a serotonin reuptake inhibitor, serotonin 5-HT1A receptor agonist, and serotonin 5-HT7 receptor antagonist.","indications":["Major depressive disorder"],"catalyst":""},{"name":"Lu AG09222","genericName":"Lu AG09222","slug":"lu-ag09222","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MK0928, gaboxadol","genericName":"MK0928, gaboxadol","slug":"mk0928-gaboxadol","phase":"phase_3","mechanism":"Gaboxadol is a selective GABA-A receptor agonist that enhances inhibitory neurotransmission in the central nervous system.","indications":["Insomnia","Anxiety disorders"],"catalyst":""},{"name":"Memantine (once daily)","genericName":"Memantine (once daily)","slug":"memantine-once-daily","phase":"marketed","mechanism":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity.","indications":["Moderate to severe Alzheimer's disease"],"catalyst":""},{"name":"Memantine (twice daily)","genericName":"Memantine (twice daily)","slug":"memantine-twice-daily","phase":"marketed","mechanism":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain.","indications":["Moderate to severe Alzheimer's disease","Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors)"],"catalyst":""},{"name":"Paliperidone and paliperidone palmitate","genericName":"Paliperidone and paliperidone palmitate","slug":"paliperidone-and-paliperidone-palmitate","phase":"phase_3","mechanism":"Paliperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms.","indications":["Schizophrenia","Schizoaffective disorder","Bipolar I disorder (acute mania and maintenance)"],"catalyst":""},{"name":"Vortioxetine (Lu AA21004)","genericName":"Vortioxetine (Lu AA21004)","slug":"vortioxetine-lu-aa21004","phase":"phase_3","mechanism":"Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"ldalopirdine 120 mg","genericName":"ldalopirdine 120 mg","slug":"ldalopirdine-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxORGxFSnFkVFVFSzlUN3MtaVdwWUxMcldycVItejFGWHg3d2NDSXFheEFBUEtINXZNNjVjX3pUbkNCWWpxWXJQb28xVHFJNUNES1NBUHp4cFBFb1NrQzliT3FtallRaHIxRDh6YXl4U3hhandRZlhoVmxMekFVMF9pUG1FQWY0cTQ3WlU0UTgtREdTTWd2THBTSkZsZEJXOWwyODVEQmduSVNLd2U5N0pMNjZHeUZtcmprdThvdnFPMGM2aW5YdlhwUWtWM050RnVDLUxxVjNpeWpzQ0lDOWozX1VZOVVFTzMtM19UMWtBc2JVNHFIS2tYMnVpeDBDZjRQdzl2eUhZcnc1alBfSzJCNGk0Q3k5dEZGX0g0Z1NiOW04NWVzOVMtbFhWcFliWWhtMkIzQjQySmcwaV93dXJPY1F5c2xrdk1WUzZ6Q210Wktxdw?oc=5","date":"2026-04-03","type":"pipeline","source":"Barchart.com","summary":"Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro -","headline":"Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-07","type":"earnings","source":"simplywall.st","summary":"H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st","headline":"H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQSDBvbjZkT3did3VpOVZjRXVWbUM2cXRrUjcyRk9mb1g3blVSaUJRMzVrVnJKTGlONkNYR3dmR0hzNVMtRlZNUFZYUlZnRkYyeTYxcXJPLTVWbExJdjhqWTN5Sm9qaGZnQ0F2UVVFLVY4TXg5OUJWUUN6dkVFOEFTOEx2Y2tXU0FHb0ZLWDRxVzJodC00Z1l1UHpZcjN5R3dYaHpFMGxtbkV5THR0bjhybHFfallDd3A5enhOM21xbFdtaWlTeG1SUDJQalFzRl94b29IZ1FZcnQ3YjVveHVjWmNvWnZySENpOEVRTEI4TzZYS1A3MDl1V01MYw?oc=5","date":"2025-12-16","type":"deal","source":"BioSpectrum Asia","summary":"Zuellig Pharma expands partnership with Lundbeck for commercialisation of neuro-psychiatric health solutions in Asia - BioSpectrum Asia","headline":"Zuellig Pharma expands partnership with Lundbeck for commercialisation of neuro-psychiatric health solutions in Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxOQU9lVllMVlRFUW16c0J6OElsT3QzdVc3RERmZ01sVlNlOUJXTkNqYVgwWllSWnVZc2FjcFZFV1R1UjY3VjhXMm0wUE1hdi1RZmppWnBNSEY5ejdHUmsxVG1VbFFwTGpfMXNHcnpPWjBkWU9td0hHWlhYWnpVNWYtdlQyamt1ejBwQjJIb1FPVGp0SGJMYlk4VVRFc0JsMWYycTMzYzc5M212NkVCOUJJaEt3c2hYTm5HdlVKVlF5QmpwVUNzRXQ0VUJNbmVPS0ozc05aQmZQR1hOakRST3k0c1RoVGI2MG9tUmYwYnJ0V1Ixb3RpM0dyZDZHczJRU1kwc2lFNEE2UzAzdHpQVE1CYno3Z3RfN2M?oc=5","date":"2025-12-16","type":"deal","source":"Media OutReach Newswire","summary":"Zuellig Pharma expands partnership with Lundbeck to support commercialization of neuro-psychiatric health solutions in Asia #ZuelligPharma #Lundbeck #Healthcare #BrainHealth #Pharmaceutical #Healthcar","headline":"Zuellig Pharma expands partnership with Lundbeck to support commercialization of neuro-psychiatric health solutions in A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZmhicEppeTc3dFl0WURRMW5MVlAxSTJZZ3VWN0NUS052SFhSWTJmcDdHQkFWVFpoUWhKU19YQk5kRUdmNDdheHZ2MmxHQkc1djlBWFFVdDUxME41YWxUN0lHMjdOdXJvQXZ5WGtxZE5qT3dVNzhMQjlDbmVFZVptZHN1Q2lXNnZReEZJVF85bnBlSHk5dmt5TzNxREh3UFRxaEFSVVdIVXFsSm5rQkR1QnhrZnBZQ2gy?oc=5","date":"2025-11-19","type":"pipeline","source":"The Business Journals","summary":"Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war - The Business Journals","headline":"Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxONVU1MHhwcmRiRGxnc20ydk5yOTJKb191clpyd1VnT2tHeUh5cTAtbERCZnBIRUZZZTFnRFFLUzVqYTZZS3Z5cl9LdVVodUV4SkFuWGNkTVdZSEhNM1UxU3FRWE5EZm1CM1pSNk5IZGdUb1BabEU3R1RBeGZZX0hrUFpRNDlYVFVZY2JmZHhZLW9naXBQdE5NelpMckNhcVAyZExTMA?oc=5","date":"2025-10-21","type":"deal","source":"BioWorld News","summary":"Lundbeck and Contera Pharma partner in neurological disorders - BioWorld News","headline":"Lundbeck and Contera Pharma partner in neurological disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOZmhZSW5UOVdPOUZxRjMxal9iQjV2dmt3RzdzVlgxQnNEVlhSZTdrSDNzWWo4VnZ5ajBhYXVmM21na0ppczZ1eXNHNmVXZUhkdUQtM2ptQXFVbTNpd0VTRnM2aVdwcDN6c2NfbENCay16Z1VPSkxVTEo0WG1ZMElxdG4wZVZ1TlpnUXdEM0ZxYjkycjFpUDFQc0ZhS1V5TVkzdUVZ?oc=5","date":"2025-10-20","type":"deal","source":"European Biotechnology Magazine","summary":"Lundbeck inks licence option deal with Contera Pharma - European Biotechnology Magazine","headline":"Lundbeck inks licence option deal with Contera Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQSFNzc0l5NHRUVFcwbDRVaG4xTHhzNkJLQ0w0V2t4azZxak5DRS1QV0RoUlhsRlRxeFZYUGRXMkJsa0xzclJMMF9UcG1IRUNzNnZDdHlVQ3J1OFBRQUc1V1RBeXdxZWFFWXhldjB2cDE0MHdtRkFybWxQNDYzN2lVSWxQc0lVRFBsWUw5MXBndDAwbWQ2aGtaaEdzc29ubjhoN0N2WnRaTVd3cGhaUVNxUjEzZ0FoMUsw?oc=5","date":"2024-12-02","type":"deal","source":"Investing.com","summary":"Longboard Pharmaceuticals concludes merger with H. Lundbeck A/S - Investing.com","headline":"Longboard Pharmaceuticals concludes merger with H. Lundbeck A/S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNRGtkcW9paWpfTEdCLUstdS1HUXFOdEhNREx1RzRkb011bkpWa1pVbmR5c3JhZXdWbUJaX29rblI3ZncxWXhQaWZNMmFlSDlfWjRSZjFyZy1EV1dCb20zcG1sbEdpdWpmb1hQbmZHNUdCbkN5VHVONFBKbVE3R0IwY0FnSVVOdzZQVXI5cF9OWlJWMS1XOWR3aWl3Yw?oc=5","date":"2024-10-14","type":"deal","source":"reuters.com","summary":"Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal - reuters.com","headline":"Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxObDFlSzRzRVNielp3ZW5uVHdLNkE1dWlIejZUdF9CaGZxdExkWXpnaGMwcFBMMkVkLUhmbDhJX3VCdVVhdDZNZk9pWFo4Zkk1cG5qTG5nM3g3S2QzLXRWSXhFVzhTUUdwclBvRktPVXpDTkxOR1hBOHphemtIZEhTSVZXWU9FMklfOUxhTDEyM3FrVXh0Q1FiUnlQSllJc1AySFB6QjU3VGxPbFgtYVA0VnVXWm5DRlhmN2lsVnNDY2h0QVJTdDZfVE01OG5ZUFFOUEU4RVdsTnl4cHl4YXg3X2NYaTNXbEV6dHp3Zk4yWmFmVFBJVDNMRlY1dkVmSFBpdkE?oc=5","date":"2024-10-14","type":"deal","source":"Business Wire","summary":"Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline - Business Wire","headline":"Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNZ3VhUW43cUpJdE44TU5VN3p4MF9lWmo3WkYxeG9VbTBDT09jUnpBaGtqYjlVbDZaSl9MNDA0Y0REODJFWnNJVkZuR2ZPMFl2ZlNMbkNlWFJqck5MR29EZ0JlczdqeTBSc2dxeVRNVkE3WXdDWWZ5RlpLdFhpTEhYUXFwdzBibzRMT0QzWlV5N09YU0o1NjVQckltNjlEejdEZEdFQnBiNnB1dHVpZTZMTm93?oc=5","date":"2024-10-14","type":"deal","source":"bloomberg.com","summary":"Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal - bloomberg.com","headline":"Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE1LNkJna2JQemVrQnRfd2lRT01Zb2tGUkp4MndNLTVtRVBsMV9GeHd6WDNjblNyZkl0UG5wTnN4TGdRclNkRThORWRPdUtybVYwTjFTaVJFRlk?oc=5","date":"2023-04-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"H. Lundbeck A/S (HLUN-B.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"H. Lundbeck A/S (HLUN-B.CO) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":15,"phaseCounts":{"phase_1":2,"phase_2":2,"marketed":5,"phase_3":6},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}